Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
08 Febrero 2022 - 7:00AM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines
company focused on the development of infectious disease vaccines
and significant opportunities within liver and respiratory rare
diseases, today announced that members of the Company’s management
team will be participating in the SVB Leerink 11th Annual Global
Healthcare Conference 2022. Joseph Payne and Andrew Sassine, the
chief executive and chief financial officers of Arcturus,
respectively, will provide a corporate overview followed by a
moderated Q&A on Friday, February 18th at 12:00 pm ET.
Conference:
SVB Leerink Global Healthcare
Conference
Presentation Date and Time:
Friday, February 18, 2022, 12:00 PM ET
Registration:
Link to presentation here
A replay of the corporate overview presentation and Q&A will
be available on the Events section of the Investor Relations
website after the conclusion of the presentation and will be
archived on the website for 90 days.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA
medicines and vaccines company with enabling technologies: (i)
LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and
(iii) mRNA drug substance along with drug product manufacturing
expertise. Arcturus’ diverse pipeline of RNA therapeutic and
vaccine candidates includes mRNA vaccine programs for SARS-CoV-2
(COVID-19) and influenza, and other programs to potentially treat
ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis
along with partnered programs including glycogen storage disease
type III (GSD III), hepatitis B virus (HBV), and non-alcoholic
steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics
platforms can be applied toward multiple types of nucleic acid
medicines including messenger RNA, small interfering RNA, replicon
RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
Arcturus’ technologies are covered by its extensive patent
portfolio (with patents and patent applications issued in the U.S.,
Europe, Japan, China and other countries). Arcturus’ commitment to
the development of novel RNA therapeutics has led to collaborations
with Janssen Pharmaceuticals, Inc., part of the Janssen
Pharmaceutical Companies of Johnson & Johnson, Ultragenyx
Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited,
CureVac AG, Duke-NUS Medical School, and the Cystic Fibrosis
Foundation. For more information visit www.ArcturusRx.com. In
addition, please connect with us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220207006010/en/
IR and Media Contacts
Arcturus Therapeutics Deepankar Roy, Ph.D. (858) 900-2682
IR@ArcturusRx.com
Kendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008
ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024